MHC-HM440-100μg / 询价
MHC-HM440-500μg / 询价
MHC-HM440-500μgx2 / 询价
表达区间及表达系统(Source)
|
Recombinant Human HLA-A*11:01&B2M&KRAS G12R (VVVGARGVGK) Monomer Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus.It contains Gly25-Thr305(HLA-A*11:01), Ile21-Met119(B2M) and VVVGARGVGK peptide [Accession | AAV53343.1(HLA-A*11:01)&P61769(B2M)&VVVGARGVGK]. |
分子量大小(Molecular Weight)
|
The protein has a predicted MW of 50.30 kDa. Due to glycosylation, the protein migrates to 53-63 kDa based on Bis-Tris PAGE result. |
纯度(Purity)
|
> 95% as determined by Bis-Tris PAGE |
内毒素(Endotoxin)
|
Less than 1EU per μg by the LAL method. |
制剂(Formulation)
|
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
重构方法(Reconstitution)
|
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
存储(Storage)
|
-20 to -80°C for 12 months as supplied from date of receipt. |
Recombinant Human HLA-A*11:01&B2M&KRAS G12R (VVVGARGVGK) Monomer Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus.It contains Gly25-Thr305(HLA-A*11:01), Ile21-Met119(B2M) and VVVGARGVGK peptide [Accession | AAV53343.1(HLA-A*11:01)&P61769(B2M)&VVVGARGVGK].
The protein has a predicted MW of 50.30 kDa. Due to glycosylation, the protein migrates to 53-63 kDa based on Bis-Tris PAGE result.
> 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC
Less than 1EU per μg by the LAL method.
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3-6 months after reconstitution.
2-8°C for 2-7 days after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
MHC; KRAS; K-Ras 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase Kras; KI-RAS; RALD
(1) Wu HZ, Xiao JQ, Xiao SS, Cheng Y. KRAS: A Promising Therapeutic Target for Cancer Treatment. Curr Top Med Chem. 2019;19(23):2081-2097. doi: 10.2174/1568026619666190905164144. PMID: 31486755.
MHC-HM440-100μg / 询价
MHC-HM440-500μg / 询价
MHC-HM440-500μgx2 / 询价
货号* | 规格* | 名称 | 数量* | |
---|---|---|---|---|
货号* | 名称 | 批号* | |
---|---|---|---|